BUSINESS

Amicus Aims to Expand Rare and Intractable Disease Pipeline in Japan

December 6, 2018
Amicus Therapeutics, which entered the Japanese market with the launch of the oral Fabry disease treatment Galafold (migalastat) in May, plans to expand its development pipeline in Japan in the fields of rare and intractable diseases starting in 2019. The…

To read the full story

BUSINESS

Takeda Pharmaceutical CEO Christophe Weber highlighted the importance of gaining a strong foothold in the world’s largest pharma market at…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…

By Yoshinori Sagehashi

Daiichi Sankyo and GlaxoSmithKline recently announced that they have agreed to dissolve their joint venture company, Japan Vaccine. The failure of this model of joint venture between a major Japanese and foreign drug maker in just six years is disappointing.Over…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…